Khushalani, N. I., Vassallo, M., Goldberg, J. D., Eroglu, Z., Kim, Y., Cao, B., Ferguson, R., Monson, K. R., Kirchhoff, T., Amato, C. M., Burke, P., Strange, A., Monk, E., Gibney, G. T., Kudchadkar, R., Markowitz, J., Brohl, A. S., Pavlick, A., Richards, A., Woods, D. M., & Weber, J. (2022). phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer, 10(11), . http://access.bl.uk/ark:/81055/vdc_100170500751.0x00000e